Dan Benjamin Teleman Acquires 6,550 Shares of Nasus Pharma (NYSEAMERICAN:NSRX) Stock

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman acquired 6,550 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were bought at an average price of $3.10 per share, for a total transaction of $20,305.00. Following the purchase, the chief executive officer owned 163,541 shares in the company, valued at approximately $506,977.10. This represents a 4.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Dan Benjamin Teleman also recently made the following trade(s):

• On Wednesday, April 22nd, Dan Benjamin Teleman bought 2,900 shares of Nasus Pharma stock. The shares were purchased at an average price of $3.76 per share, for a total transaction of $10,904.00.

Nasus Pharma Stock Performance

NYSEAMERICAN NSRX opened at $3.30 on Wednesday. The stock’s fifty day moving average price is $2.98. Nasus Pharma Ltd. has a 1 year low of $1.98 and a 1 year high of $9.99.

Wall Street Analysts Forecast Growth

Separately, Citizens Jmp lowered their price target on Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $18.00.

About Nasus Pharma

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.